Research programme: Zika virus-like particle vaccine - GeoVax Labs

Drug Profile

Research programme: Zika virus-like particle vaccine - GeoVax Labs

Alternative Names: GEO ZM02; GOVX-ZM01; ZIKV Envelope protein vaccine

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GeoVax Labs
  • Developer GeoVax Labs; University of Georgia
  • Class Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Zika virus infection

Most Recent Events

  • 19 Jun 2017 GeoVax Labs receives SBIR grant from National Institutes of Health for GEO ZM02 and ZIKV Envelope protein development in Zika virus infection
  • 19 Jun 2017 GeoVax Labs plans to initiate preclinical testing and phase I trial for GEO ZM02 and ZIKV Envelope protein vaccine for Zika virus infection
  • 03 Oct 2016 Preclinical trials in Zika virus infection (Prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top